Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 599 entries
Sorted by: Best Match Show Resources per page
Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.

Pharmaceutics

Löhr JM, Haas SL, Kröger JC, Friess HM, Höft R, Goretzki PE, Peschel C, Schweigert M, Salmons B, Gunzburg WH.
PMID: 25116885
Pharmaceutics. 2014 Aug 11;6(3):447-66. doi: 10.3390/pharmaceutics6030447.

Despite progress in the treatment of pancreatic cancer, there is still a need for improved therapies. In this manuscript, we report clinical experience with a new therapy for the treatment of pancreatic cancer involving the implantation of encapsulated cells...

Cite
Löhr JM, Haas SL, Kröger JC, et al. Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer. Pharmaceutics. 2014;6(3):447-66doi: 10.3390/pharmaceutics6030447.
Löhr, J. M., Haas, S. L., Kröger, J. C., Friess, H. M., Höft, R., Goretzki, P. E., Peschel, C., Schweigert, M., Salmons, B., & Gunzburg, W. H. (2014). Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer. Pharmaceutics, 6(3), 447-66. https://doi.org/10.3390/pharmaceutics6030447
Löhr, J Matthias, et al. "Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer." Pharmaceutics vol. 6,3 (2014): 447-66. doi: https://doi.org/10.3390/pharmaceutics6030447
Löhr JM, Haas SL, Kröger JC, Friess HM, Höft R, Goretzki PE, Peschel C, Schweigert M, Salmons B, Gunzburg WH. Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer. Pharmaceutics. 2014 Aug 11;6(3):447-66. doi: 10.3390/pharmaceutics6030447. PMID: 25116885; PMCID: PMC4190529.
Copy Download .nbib Format: NLM
Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis.

Molecular and clinical oncology

Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L.
PMID: 25798279
Mol Clin Oncol. 2015 Mar;3(2):420-424. doi: 10.3892/mco.2014.467. Epub 2014 Nov 25.

This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small-cell lung cancer (SCLC). The Cochrane Library, Embase, MEDLINE and...

Cite
Yang H, Ma Y, Liu Z, et al. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2014;3(2):420-424doi: 10.3892/mco.2014.467.
Yang, H., Ma, Y., Liu, Z., Wang, Z., Han, B., & Ma, L. (2015). Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Molecular and clinical oncology, 3(2), 420-424. https://doi.org/10.3892/mco.2014.467
Yang, Huizhen, et al. "Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis." Molecular and clinical oncology vol. 3,2 (2015): 420-424. doi: https://doi.org/10.3892/mco.2014.467
Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2015 Mar;3(2):420-424. doi: 10.3892/mco.2014.467. Epub 2014 Nov 25. PMID: 25798279; PMCID: PMC4360815.
Copy Download .nbib Format: NLM
Simultaneous Low- and High-Grade Primary Leiomyosarcomas in Two Separate Organs in a Thirty-Year Survivor of Hereditary Retinoblastoma.

Case reports in oncological medicine

Moore K, Tawfik O, Hays A, Opole I.
PMID: 26843997
Case Rep Oncol Med. 2015;2015:968567. doi: 10.1155/2015/968567. Epub 2015 Dec 30.

Patients with hereditary retinoblastoma have a heightened risk of developing subsequent bone and soft tissue sarcomas, exacerbated by radiation and alkylating chemotherapy. Secondary leiomyosarcomas are rare. A 29-year-old patient with bilateral retinoblastoma history presented with concurrent, independent malignancies found...

Cite
Moore K, Tawfik O, Hays A, et al. Simultaneous Low- and High-Grade Primary Leiomyosarcomas in Two Separate Organs in a Thirty-Year Survivor of Hereditary Retinoblastoma. Case Rep Oncol Med. 2015;2015:968567doi: 10.1155/2015/968567.
Moore, K., Tawfik, O., Hays, A., & Opole, I. (2015). Simultaneous Low- and High-Grade Primary Leiomyosarcomas in Two Separate Organs in a Thirty-Year Survivor of Hereditary Retinoblastoma. Case reports in oncological medicine, 2015968567. https://doi.org/10.1155/2015/968567
Moore, Katherine, et al. "Simultaneous Low- and High-Grade Primary Leiomyosarcomas in Two Separate Organs in a Thirty-Year Survivor of Hereditary Retinoblastoma." Case reports in oncological medicine vol. 2015 (2015): 968567. doi: https://doi.org/10.1155/2015/968567
Moore K, Tawfik O, Hays A, Opole I. Simultaneous Low- and High-Grade Primary Leiomyosarcomas in Two Separate Organs in a Thirty-Year Survivor of Hereditary Retinoblastoma. Case Rep Oncol Med. 2015;2015:968567. doi: 10.1155/2015/968567. Epub 2015 Dec 30. PMID: 26843997; PMCID: PMC4710913.
Copy Download .nbib Format: NLM
Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors.

Sarcoma

Hirbe AC, Cosper PF, Dahiya S, Van Tine BA.
PMID: 28546782
Sarcoma. 2017;2017:3761292. doi: 10.1155/2017/3761292. Epub 2017 May 04.

No abstract available.

Cite
Hirbe AC, Cosper PF, Dahiya S, et al. Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017;2017:3761292doi: 10.1155/2017/3761292.
Hirbe, A. C., Cosper, P. F., Dahiya, S., & Van Tine, B. A. (2017). Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma, 20173761292. https://doi.org/10.1155/2017/3761292
Hirbe, Angela C, et al. "Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors." Sarcoma vol. 2017 (2017): 3761292. doi: https://doi.org/10.1155/2017/3761292
Hirbe AC, Cosper PF, Dahiya S, Van Tine BA. Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017;2017:3761292. doi: 10.1155/2017/3761292. Epub 2017 May 04. PMID: 28546782; PMCID: PMC5435903.
Copy Download .nbib Format: NLM
Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma.

Case reports in oncology

Mota JM, Scaranti M, Fonseca LG, Tolói DA, de Camargo VP, Munhoz RR, Feher O, Hoff PM.
PMID: 27721772
Case Rep Oncol. 2016 Aug 24;9(2):481-487. doi: 10.1159/000448111. eCollection 2016.

BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of vascular origin that typically arises from the skin or soft tissues as a solitary tumor. The optimal therapy for this disease is still unknown. We report the case of an...

Cite
Mota JM, Scaranti M, Fonseca LG, et al. Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. Case Rep Oncol. 2016;9(2):481-487doi: 10.1159/000448111.
Mota, J. M., Scaranti, M., Fonseca, L. G., Tolói, D. A., de Camargo, V. P., Munhoz, R. R., Feher, O., & Hoff, P. M. (2016). Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. Case reports in oncology, 9(2), 481-487. https://doi.org/10.1159/000448111
Mota, José Maurício, et al. "Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma." Case reports in oncology vol. 9,2 (2016): 481-487. doi: https://doi.org/10.1159/000448111
Mota JM, Scaranti M, Fonseca LG, Tolói DA, de Camargo VP, Munhoz RR, Feher O, Hoff PM. Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. Case Rep Oncol. 2016 Aug 24;9(2):481-487. doi: 10.1159/000448111. eCollection 2016. PMID: 27721772; PMCID: PMC5043218.
Copy Download .nbib Format: NLM
Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.

Case reports in oncological medicine

Jannin A, Hennart B, Adenis A, Chauffert B, Penel N.
PMID: 29098099
Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26.

Alveolar rhabdomyosarcoma (AR) in adult patients is an exceptional malignancy. Management of AR is based on (neo)adjuvant chemotherapy combining ifosfamide, vincristine, and actinomycin D and local curative-intent surgery/radiotherapy. In cases of relapsing AR, the combination of temozolomide/irinotecan is regarded...

Cite
Jannin A, Hennart B, Adenis A, et al. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case Rep Oncol Med. 2017;2017:2683478doi: 10.1155/2017/2683478.
Jannin, A., Hennart, B., Adenis, A., Chauffert, B., & Penel, N. (2017). Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case reports in oncological medicine, 20172683478. https://doi.org/10.1155/2017/2683478
Jannin, Arnaud, et al. "Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism." Case reports in oncological medicine vol. 2017 (2017): 2683478. doi: https://doi.org/10.1155/2017/2683478
Jannin A, Hennart B, Adenis A, Chauffert B, Penel N. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26. PMID: 29098099; PMCID: PMC5634569.
Copy Download .nbib Format: NLM
Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Murakami Y, Tabata K, Sugita A, Mochizuki K, Maeyama R, Okazaki M, Nishi M, Matsumoto K, Fujita T, Satoh T, Jiang SX, Saegusa M, Iwamura M.
PMID: 24839496
Can Urol Assoc J. 2014 Mar;8(3):E263-5. doi: 10.5489/cuaj.1648.

A 22-year-old man was referred to our hospital with macroscopic hematuria and consistent anal pain. Magnetic resonance imaging revealed an enlarged prostate tumour invading the bladder and rectum. A biopsy revealed an unclassified spindle cell sarcoma. Subsequently, radical cystoprostatectomy...

Cite
Murakami Y, Tabata K, Sugita A, et al. Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Can Urol Assoc J. 2014;8(3):E263-5doi: 10.5489/cuaj.1648.
Murakami, Y., Tabata, K., Sugita, A., Mochizuki, K., Maeyama, R., Okazaki, M., Nishi, M., Matsumoto, K., Fujita, T., Satoh, T., Jiang, S. X., Saegusa, M., & Iwamura, M. (2014). Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 8(3), E263-5. https://doi.org/10.5489/cuaj.1648
Murakami, Yasukiyo, et al. "Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 8,3 (2014): E263-5. doi: https://doi.org/10.5489/cuaj.1648
Murakami Y, Tabata K, Sugita A, Mochizuki K, Maeyama R, Okazaki M, Nishi M, Matsumoto K, Fujita T, Satoh T, Jiang SX, Saegusa M, Iwamura M. Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Can Urol Assoc J. 2014 Mar;8(3):E263-5. doi: 10.5489/cuaj.1648. PMID: 24839496; PMCID: PMC4001657.
Copy Download .nbib Format: NLM
The interaction of ifosfamide and aprepitant in gynecologic malignancies.

Gynecologic oncology case reports

Shindorf ML, Manahan KJ, Geisler JP.
PMID: 24371715
Gynecol Oncol Case Rep. 2013 Jun 12;6:34-5. doi: 10.1016/j.gynor.2013.06.002. eCollection 2013.

•Aprepitant combined with ifosfamide may lead to encephalopathy.•Aprepitant-ifosfamide induced encephalopathy was of short duration in these cases.

Cite
Shindorf ML, Manahan KJ, Geisler JP. The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecol Oncol Case Rep. 2013;6:34-5doi: 10.1016/j.gynor.2013.06.002.
Shindorf, M. L., Manahan, K. J., & Geisler, J. P. (2013). The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecologic oncology case reports, 634-5. https://doi.org/10.1016/j.gynor.2013.06.002
Shindorf, Mackenzie L, et al. "The interaction of ifosfamide and aprepitant in gynecologic malignancies." Gynecologic oncology case reports vol. 6 (2013): 34-5. doi: https://doi.org/10.1016/j.gynor.2013.06.002
Shindorf ML, Manahan KJ, Geisler JP. The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecol Oncol Case Rep. 2013 Jun 12;6:34-5. doi: 10.1016/j.gynor.2013.06.002. eCollection 2013. PMID: 24371715; PMCID: PMC3862235.
Copy Download .nbib Format: NLM
Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer.

Cancer research and treatment

Kim SJ, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim KT, Choi YH, Kim JS.
PMID: 26680898
Cancer Res Treat. 2002 Dec;34(6):421-5. doi: 10.4143/crt.2002.34.6.421.

PURPOSE: The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung cancer (SCLC). The schedule dependence, and equal efficacy, of the oral and intravenous dosing of etoposide has led...

Cite
Kim SJ, Sung HJ, Park KH, et al. Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer. Cancer Res Treat. 2002;34(6):421-5doi: 10.4143/crt.2002.34.6.421.
Kim, S. J., Sung, H. J., Park, K. H., Yoon, S. Y., Oh, S. C., Seo, J. H., Choi, C. W., Kim, B. S., Shin, S. W., Kim, Y. H., Kim, K. T., Choi, Y. H., & Kim, J. S. (2002). Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer. Cancer research and treatment, 34(6), 421-5. https://doi.org/10.4143/crt.2002.34.6.421
Kim, Seok Jin, et al. "Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer." Cancer research and treatment vol. 34,6 (2002): 421-5. doi: https://doi.org/10.4143/crt.2002.34.6.421
Kim SJ, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim KT, Choi YH, Kim JS. Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer. Cancer Res Treat. 2002 Dec;34(6):421-5. doi: 10.4143/crt.2002.34.6.421. PMID: 26680898.
Copy Download .nbib Format: NLM
Synovial sarcoma of the kidney in a young patient with a review of the literature.

Rare tumors

Abbas M, Dämmrich ME, Braubach P, Meinardus A, Kramer MW, Merseburger AS, Herrmann TR, Grünwald V, Kreipe HH.
PMID: 25002954
Rare Tumors. 2014 Jun 16;6(2):5393. doi: 10.4081/rt.2014.5393. eCollection 2014 May 13.

Synovial sarcoma (SS) is a soft tissue, generally deep seated neoplasms that occurs generally in the proximity of large joints. We report of a case of a 33-year-old man who was diagnosed with primary SS of the kidney which...

Cite
Abbas M, Dämmrich ME, Braubach P, et al. Synovial sarcoma of the kidney in a young patient with a review of the literature. Rare Tumors. 2014;6(2):5393doi: 10.4081/rt.2014.5393.
Abbas, M., Dämmrich, M. E., Braubach, P., Meinardus, A., Kramer, M. W., Merseburger, A. S., Herrmann, T. R., Grünwald, V., & Kreipe, H. H. (2014). Synovial sarcoma of the kidney in a young patient with a review of the literature. Rare tumors, 6(2), 5393. https://doi.org/10.4081/rt.2014.5393
Abbas, Mahmoud, et al. "Synovial sarcoma of the kidney in a young patient with a review of the literature." Rare tumors vol. 6,2 (2014): 5393. doi: https://doi.org/10.4081/rt.2014.5393
Abbas M, Dämmrich ME, Braubach P, Meinardus A, Kramer MW, Merseburger AS, Herrmann TR, Grünwald V, Kreipe HH. Synovial sarcoma of the kidney in a young patient with a review of the literature. Rare Tumors. 2014 Jun 16;6(2):5393. doi: 10.4081/rt.2014.5393. eCollection 2014 May 13. PMID: 25002954; PMCID: PMC4083674.
Copy Download .nbib Format: NLM
Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis.

American journal of translational research

Kim EK, Yoon G, Kim HS.
PMID: 27347355
Am J Transl Res. 2016 May 15;8(5):2459-67. eCollection 2016.

Chemotherapy is a common type of preoperative neoadjuvant treatment and postoperative adjuvant or palliative therapy for many different types of malignancies. Certain chemotherapeutic agents can induce bizarre epithelial atypia that mimics malignancy. Unfamiliarity with these changes could potentially cause...

Cite
Kim EK, Yoon G, Kim HS. Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis. Am J Transl Res. 2016;8(5):2459-67
Kim, E. K., Yoon, G., & Kim, H. S. (2016). Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis. American journal of translational research, 8(5), 2459-67.
Kim, Eun Kyung, et al. "Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis." American journal of translational research vol. 8,5 (2016): 2459-67.
Kim EK, Yoon G, Kim HS. Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis. Am J Transl Res. 2016 May 15;8(5):2459-67. eCollection 2016. PMID: 27347355; PMCID: PMC4891460.
Copy Download .nbib Format: NLM
Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction.

Journal of pharmacology & pharmacotherapeutics

Kataria PS, Kendre PP, Patel AA.
PMID: 28405136
J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):38-40. doi: 10.4103/jpp.JPP_182_16.

Central nervous system (CNS) toxicity has been reported in approximately 10%-30% of patients receiving intravenous infusions of ifosfamide. Encephalopathy is a rare but serious CNS adverse reaction in these patients, and although usually transient and reversible, may cause persistent...

Cite
Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. J Pharmacol Pharmacother. 2017;8(1):38-40doi: 10.4103/jpp.JPP_182_16.
Kataria, P. S., Kendre, P. P., & Patel, A. A. (2017). Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. Journal of pharmacology & pharmacotherapeutics, 8(1), 38-40. https://doi.org/10.4103/jpp.JPP_182_16
Kataria, Pritam Sureshchandra, et al. "Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction." Journal of pharmacology & pharmacotherapeutics vol. 8,1 (2017): 38-40. doi: https://doi.org/10.4103/jpp.JPP_182_16
Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):38-40. doi: 10.4103/jpp.JPP_182_16. PMID: 28405136; PMCID: PMC5370329.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 599 entries